Literature DB >> 15350304

Molecular cytogenetic characterization of the mantle cell lymphoma cell line GRANTA-519.

C Rudolph1, D Steinemann, N Von Neuhoff, D Gadzicki, T Ripperger, H G Drexler, K Mrasek, T Liehr, U Claussen, M Emura, E Schrock, B Schlegelberger.   

Abstract

Combining fluorescence R-banding, fluorescence in situ hybridization and spectral karyotyping allowed us to precisely define chromosomal breakpoints, gains, losses and a newly detected amplification in the human mantle cell lymphoma (MCL) cell line GRANTA-519. GRANTA-519 is characterized by the t(11;14)(q13;q32) resulting in overexpression of cyclin D1, a key player in cell cycle control. Hitherto unresolved complex rearrangements involve 1p, 1q, 3cen, 9p, 11q, 12p, 12q, 16p, 17p, and 18cen. Moreover, a 4- to 6-fold gain of sequences on 18q leads to a low-level amplification of the BCL2 gene and to an overexpression of the BCL2 protein. These results provide the basis for the identification of not only candidate oncogenes responsible for MCL in gained regions, but also for the identification of putative tumor suppressor genes in commonly deleted regions like 1p22, which would eventually enable functional studies of these genes.

Entities:  

Mesh:

Year:  2004        PMID: 15350304     DOI: 10.1016/j.cancergencyto.2004.01.006

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  12 in total

1.  Proapoptotic protein BIM as a novel prognostic marker in mantle cell lymphoma.

Authors:  Jeff D Wang; Samuel G Katz; Elizabeth A Morgan; David T Yang; Xueliang Pan; Mina L Xu
Journal:  Hum Pathol       Date:  2019-08-16       Impact factor: 3.466

2.  Molecular signatures for CCN1, p21 and p27 in progressive mantle cell lymphoma.

Authors:  Afak Rasheed Salman Zaidi; Sadie Dresman; Charlotte Burt; Simon Rule; Lynn McCallum
Journal:  J Cell Commun Signal       Date:  2018-11-21       Impact factor: 5.782

3.  Mantle cell lymphoma in cyclin D1 transgenic mice with Bim-deficient B cells.

Authors:  Samuel G Katz; James L Labelle; Hailong Meng; Regina P Valeriano; Jill K Fisher; Heather Sun; Scott J Rodig; Steven H Kleinstein; Loren D Walensky
Journal:  Blood       Date:  2013-12-18       Impact factor: 22.113

Review 4.  Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic Malignancies.

Authors:  Fevzi F Yalniz; William G Wierda
Journal:  Drugs       Date:  2019-08       Impact factor: 9.546

5.  Responses in mantle cell lymphoma cells to SNS-032 depend on the biological context of each cell line.

Authors:  Rong Chen; Sherri Chubb; Tiewei Cheng; Rachael E Hawtin; Varsha Gandhi; William Plunkett
Journal:  Cancer Res       Date:  2010-07-27       Impact factor: 12.701

6.  Measles virus entry through the signaling lymphocyte activation molecule governs efficacy of mantle cell lymphoma radiovirotherapy.

Authors:  Tanner S Miest; Marie Frenzke; Roberto Cattaneo
Journal:  Mol Ther       Date:  2013-08-05       Impact factor: 11.454

7.  Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma.

Authors:  Michael A Dengler; Charis E Teh; Rachel Thijssen; Lahiru Gangoda; Ping Lan; Marco J Herold; Daniel H Gray; Gemma L Kelly; Andrew W Roberts; Jerry M Adams
Journal:  Oncogene       Date:  2019-11-26       Impact factor: 9.867

8.  High contrast tumor imaging with radio-labeled antibody Fab fragments tailored for optimized pharmacokinetics via PASylation.

Authors:  Claudia T Mendler; Lars Friedrich; Iina Laitinen; Martin Schlapschy; Markus Schwaiger; Hans-Jürgen Wester; Arne Skerra
Journal:  MAbs       Date:  2015       Impact factor: 5.857

9.  Replication-induced DNA damage after PARP inhibition causes G2 delay, and cell line-dependent apoptosis, necrosis and multinucleation.

Authors:  Idun Dale Rein; Kirsti Solberg Landsverk; Francesca Micci; Sebastian Patzke; Trond Stokke
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

10.  Inhibition of estrogen biosynthesis enhances lymphoma growth in mice.

Authors:  Gergely Talaber; Konstantin Yakimchuk; Jiyu Guan; Jose Inzunza; Sam Okret
Journal:  Oncotarget       Date:  2016-04-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.